Jorgensen Sarah C J, Drover Samantha S M, Fell Deshayne B, Austin Peter C, D'Souza Rohan, Guttmann Astrid, Buchan Sarah A, Wilson Sarah E, Nasreen Sharifa, Brown Kevin A, Schwartz Kevin L, Tadrous Mina, Wilson Kumanan, Kwong Jeffrey C
Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada.
ICES, Toronto, Ontario, Canada.
BMJ Med. 2024 Sep 16;3(1):e000743. doi: 10.1136/bmjmed-2023-000743. eCollection 2024.
To examine the association between maternal mRNA covid-19 vaccination during the first trimester of pregnancy and the prevalence of major congenital anomalies in offspring.
Population based cohort study with sibling matched analysis.
Multiple health administrative databases, linked and analysed at ICES, an independent, non-profit research institute that collects and analyses healthcare and demographic data, Ontario, Canada, from 16 October 2021 to 1 May 2023.
174 296 singleton live births >20 weeks' gestation with an expected birth date between 16 October 2021 and 1 May 2023: 34 181 (20%) born to mothers who received one or two doses of an mRNA covid-19 vaccine in the first trimester and 34 951 (20%) born to mothers who did not receive a vaccine before or during pregnancy. The sibling matched analysis included 13 312 infants exposed to a covid-19 vaccine in the first trimester and 15 089 matched older siblings with the same mother, with an expected birth date after 16 October 2016 and no reported in utero exposure to a covid-19 vaccine.
Major congenital anomalies, overall and grouped by specific organ systems, diagnosed within 28 days of birth.
Major congenital anomalies were present in 832 (24.3 per 1000 live births) infants exposed to an mRNA covid-19 vaccine in the first trimester compared with 927 (26.5 per 1000 live births) infants not exposed to a vaccine, resulting in an adjusted prevalence ratio of 0.89 (95% confidence interval (CI) 0.79 to 1.01). Major congenital anomalies were present in 283 (21.3 per 1000 live births) and 343 (22.7 per 1000 live births) infants exposed to an mRNA covid-19 vaccine in the first trimester and their older siblings not exposed to a vaccine, respectively (adjusted prevalence ratio 0.91, 95% CI 0.77 to 1.07). First trimester vaccination was not associated with an increase in major congenital anomalies grouped by specific organ system in the primary or sibling matched analyses. Results were similar across a range of subgroup and sensitivity analyses.
In this large population based cohort study and sibling matched analysis, mRNA covid-19 vaccination during the first trimester of pregnancy was not associated with an increase in major congenital anomalies in offspring, overall or grouped by organ system.
研究孕期头三个月母体mRNA新冠疫苗接种与后代主要先天性异常患病率之间的关联。
基于人群的队列研究,并进行同胞匹配分析。
多个卫生行政数据库,由ICES(一家独立的非营利性研究机构,收集和分析医疗保健及人口数据)进行链接和分析,数据来自2021年10月16日至2023年5月1日期间的加拿大安大略省。
174296例单胎活产儿,妊娠周数>20周,预期出生日期在2021年10月16日至2023年5月1日之间:34181例(20%)为孕期头三个月接受一剂或两剂mRNA新冠疫苗的母亲所生,34951例(20%)为孕期未接种疫苗的母亲所生。同胞匹配分析纳入了13312例孕期头三个月接触过新冠疫苗的婴儿以及15089例与其母亲相同、预期出生日期在2016年10月16日之后且未报告子宫内接触过新冠疫苗的同胞。
出生后28天内诊断的主要先天性异常,总体情况以及按特定器官系统分组的情况。
孕期头三个月接触过mRNA新冠疫苗的婴儿中有832例(每1000例活产儿中有24.3例)存在主要先天性异常,未接触疫苗的婴儿中有927例(每1000例活产儿中有26.5例),调整后的患病率比值为0.89(95%置信区间(CI)0.79至1.01)。孕期头三个月接触过mRNA新冠疫苗的婴儿中有283例(每1000例活产儿中有21.3例)存在主要先天性异常,其未接触疫苗的同胞中有343例(每1000例活产儿中有22.7例)(调整后的患病率比值为0.91,95%CI0.77至1.07)。在主要分析或同胞匹配分析中,孕期头三个月接种疫苗与按特定器官系统分组的主要先天性异常增加无关。在一系列亚组分析和敏感性分析中结果相似。
在这项基于人群的大型队列研究和同胞匹配分析中,孕期头三个月接种mRNA新冠疫苗与后代总体或按器官系统分组的主要先天性异常增加无关。